BEDFORD, Mass.--(BUSINESS WIRE)--Cambridge Heart, Inc. (OTCBB-CAMH) announced today that a conference
call has been scheduled for November 2, 2006 at 4:30 p.m. eastern to
discuss the Company’s third quarter financial
results, as well as recent Company developments. The call will be hosted
by Mr. Jeffery Langan, the Company’s President
and CEO, and Mr. Roderick de Greef, its Chief Financial Officer.
Interested parties may participate by dialing (866) 356-4279 or (617)
597-5394 from outside the U.S. utilizing Passcode 82383362.
Persons unable to participate may listen to a recorded replay at any
time during the 48 hours immediately following the conference call by
dialing (888) 286-8010 or (617) 801-6888 from outside the U.S. The code
for the replay is 44763245. The replay will be available beginning
approximately two hours after the call ends. The conference call will
also be available by webcast on the Company's web site at www.cambridgeheart.com.
About the Cambridge Heart Microvolt T-Wave Alternans Test
The Cambridge Heart Microvolt T-Wave Alternans Test measures extremely
subtle beat-to-beat fluctuations in a person’s
heartbeat called T-wave alternans. These tiny heartbeat variations –
measured at one millionth of a volt – are
detected in any clinical setting where titration of the heart rate is
possible. The preparation for the test consists of placing proprietary
sensors on a patient’s chest. Extensive
clinical research has shown that patients with symptoms of or at risk of
life threatening arrhythmias who test positive for T-wave alternans are
at significant risk for subsequent sudden cardiac events including
sudden death, while those who test negative are at minimal risk.
About Cambridge Heart, Inc.
Cambridge Heart is engaged in the research, development and
commercialization of products for the non-invasive diagnosis of cardiac
disease. Using innovative technologies, the Company is addressing such
key problems in cardiac diagnosis as the identification of those at risk
of sudden cardiac arrest. The Company’s
products incorporate its proprietary technology, Microvolt T-Wave
Alternans, and is the first diagnostic tool cleared by the U.S. Food and
Drug Administration to non-invasively measure microvolt levels of T-wave
alternans. The Company, founded in 1990, is based in Bedford,
Massachusetts and is traded on the OTCBB under the symbol CAMH.
Cambridge Heart can be found on the World Wide Web at www.cambridgeheart.com
